Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DCL000351

Drug Information
SynonymsPazopanib; CID10113978; GW-786034; I09-0358; 790713-33-6; 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonami; GW786034; 444731-52-6; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; AKOS005145819; UNII-7RN5DR86CK; ST51053493; CHEMBL477772; MolPort-006-827-156; Votrient; GW 786034; Kinome_3790; Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-; Pazopanib [INN]; Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-
IndicationAdvanced / metastatic renal cancer
[ICD9: 189   ICD10: C64]
Phase III    [1]
Solid tumours, NSCLC
[ICD9: 140-199, 162, 210-229   ICD10: C00-C75, C33, C34, C7A, C7B, D10-D36, D3A]
Phase II completed    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESCC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 444731-52-6
PubChem Compound IDCID 10113978.
PubChem Substance IDSID 15102663.
SuperDrug ATC IDL01XE11
TargetMast/stem cell growth factor receptorInhibitor[2][3][4]
Mast/stem cell growth factor receptorMultitarget[2][3][4]
Platelet-derived growth factor receptorInhibitor[2][3][4]
Platelet-derived growth factor receptorMultitarget[2][3][4]
Vascular endothelial growth factor receptor 2Inhibitor[2][3][4]
Vascular endothelial growth factor receptor 2Multitarget[2][3][4]
Ref 1Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. To Reference
Ref 2A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. To Reference
Ref 3GSK. Product Development Pipeline. February 2009. To Reference
Ref 4Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543